Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05609968 |
|---|---|
| Brief Title: | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) |
| First Submitted : | November 2, 2022 |
| First Submitted that Met QC Criteria : | November 2, 2022 |
| First Posted : | November 8, 2022 |
| Last Update Submitted that Met QC Criteria : | April 4, 2024 |
| Last Update Posted : | April 5, 2024 |